Epigenetic metabolite lipid nanoparticles alleviate venous thrombosis via bone marrow reprogramming.

ABSTRACT: Targeting the coagulation cascade is a mainstay approach to therapy for thrombosis. One of the most prevalent complications of anticoagulation is a significant bleeding risk that can result in hospitalization. Recent studies on immunothrombosis (ie, inflammation-linked thrombosis) proposed myeloid cells, especially neutrophils, to actively participate in thrombus formation through neutrophil extracellular traps (NETosis) and activation of inflammatory pathways. Here, we developed lipid nanoparticles (LNPs) with coagulation cascade-independent action that target neutrophils to alleviate venous thrombosis. A single intravenous dose of immunomodulatory metabolite itaconate (ITA)-bearing LNPs (ITA-LNPs) targeted >90% of bone marrow-resident neutrophils, but not macrophages or T lymphocytes. IT

SUBMITTER: Di L 

PROVIDER: S-EPMC12682971 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature